TNF-α-dependent hematopoiesis following Bcl11b deletion in T cells restricts metastatic melanoma

Journal of Immunology

Volumn 192, Issue 4, 2014, Pages 1946-1953

  Uddin, Mohammad N ^a   Zhang, Yubin ^a   Harton, Jonathan A ^a   MacNamara, Katherine C ^a   Avram, Dorina ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; BCL11B PROTEIN; GRANZYME B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DEGRANULATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; LUNG METASTASIS; LYMPHOCYTE PROLIFERATION; METASTATIC MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTIGENS, LY; ARGINASE; CD8-POSITIVE T-LYMPHOCYTES; CELL DEGRANULATION; CELL PROLIFERATION; GENE DELETION; GRANZYMES; HEMATOPOIESIS; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPHOCYTE COUNT; MELANOMA; MICE; MICE, TRANSGENIC; MYELOID CELLS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B; REPRESSOR PROTEINS; SPLEEN; T-LYMPHOCYTES, REGULATORY; TUMOR BURDEN; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84896723703     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301976     Document Type: Article

References (52)

1. Perez-Diez, A., N. T. Joncker, K. Choi, W. F. Chan, C. C. Anderson, O. Lantz, and P. Matzinger. 2007. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109: 5346-5354.
2. Xie, Y., A. Akpinarli, C. Maris, E. L. Hipkiss, M. Lane, E. K. Kwon, P. Muranski, N. P. Restifo, and P. A. Antony. 2010. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207: 651-667.
3. Schietinger, A., M. Philip, R. B. Liu, K. Schreiber, and H. Schreiber. 2010. Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J. Exp. Med. 207: 2469-2477.
4. Fransen, M. F., M. Sluijter, H. Morreau, R. Arens, and C. J. Melief. 2011. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin. Cancer Res. 17: 2270-2280.
5. Vujanovic, L., and L. H. Butterfield. 2007. Melanoma cancer vaccines and antitumor T cell responses. J. Cell. Biochem. 102: 301-310.
6. + T cells in metastases from melanoma patients. J. Clin. Invest. 121: 2350-2360.
7. Matsuda, T., K. Maekawa, K. Asano, and T. Hisamitsu. 2011. Suppressive effect of juzen-taiho-to on lung metastasis of b16 melanoma cells in vivo. Evid. Based Complement. Alternat. Med. 2011: 743153.
8. Voskoboinik, I., M. J. Smyth, and J. A. Trapani. 2006. Perforin-mediated targetcell death and immune homeostasis. Nat. Rev. Immunol. 6: 940-952.
9. Vivier, E., E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini. 2008. Functions of natural killer cells. Nat. Immunol. 9: 503-510.
10. Smyth, M. J., J. Swann, E. Cretney, N. Zerafa, W. M. Yokoyama, and Y. Hayakawa. 2005. NKG2D function protects the host from tumor initiation. J. Exp. Med. 202: 583-588.
11. Guerra, N., Y. X. Tan, N. T. Joncker, A. Choy, F. Gallardo, N. Xiong, S. Knoblaugh, D. Cado, N. M. Greenberg, and D. H. Raulet. 2008. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571-580.
12. Burke, S., T. Lakshmikanth, F. Colucci, and E. Carbone. 2010. New views on natural killer cell-based immunotherapy for melanoma treatment. Trends Immunol. 31: 339-345.
13. Lakshmikanth, T., S. Burke, T. H. Ali, S. Kimpfler, F. Ursini, L. Ruggeri, M. Capanni, V. Umansky, A. Paschen, A. Sucker, et al. 2009. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J. Clin. Invest. 119: 1251-1263.
14. Gordon, S., and F. O. Martinez. 2010. Alternative activation of macrophages: mechanism and functions. Immunity 32: 593-604.
15. Zamarron, B. F., and W. Chen. 2011. Dual roles of immune cells and their factors in cancer development and progression. Int. J. Biol. Sci. 7: 651-658.
16. Condamine, T., and D. I. Gabrilovich. 2011. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32: 19-25.
17. Gabrilovich, D. I., S. Ostrand-Rosenberg, and V. Bronte. 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12: 253-268.
18. van Horssen, R., T. L. Ten Hagen, and A. M. Eggermont. 2006. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11: 397-408.
19. ten Hagen, T. L., A. L. Seynhaeve, and A. M. Eggermont. 2008. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. Immunol. Rev. 222: 299-315.
20. Baxevanis, C. N., I. F. Voutsas, O. E. Tsitsilonis, M. L. Tsiatas, A. D. Gritzapis, and M. Papamichail. 2000. Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice. Eur. J. Immunol. 30: 1957-1966.
21. Ostensen, M. E., D. L. Thiele, and P. E. Lipsky. 1987. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells. J. Immunol. 138: 4185-4191.
22. Avram, D., A. Fields, T. Senawong, A. Topark-Ngarm, and M. Leid. 2002. COUPTF (chicken ovalbumin upstream promoter transcription factor)-interacting protein 1 (CTIP1) is a sequence-specific DNA binding protein. Biochem. J. 368: 555-563.
23. Avram, D., A. Fields, K. Pretty On Top, D. J. Nevrivy, J. E. Ishmael, and M. Leid. 2000. Isolation of a novel family of C(2)H(2) zinc finger proteins implicated in transcriptional repression mediated by chicken ovalbumin upstream promoter transcription factor (COUP-TF) orphan nuclear receptors. J. Biol. Chem. 275: 10315-10322.
24. Wakabayashi, Y., H. Watanabe, J. Inoue, N. Takeda, J. Sakata, Y. Mishima, J. Hitomi, T. Yamamoto, M. Utsuyama, O. Niwa, et al. 2003. Bcl11b is required for differentiation and survival of alphabeta T lymphocytes. Nat. Immunol. 4: 533-539.
25. Albu, D. I., D. Feng, D. Bhattacharya, N. A. Jenkins, N. G. Copeland, P. Liu, and D. Avram. 2007. BCL11B is required for positive selection and survival of double-positive thymocytes. J. Exp. Med. 204: 3003-3015.
26. Li, P., S. Burke, J. Wang, X. Chen, M. Ortiz, S. C. Lee, D. Lu, L. Campos, D. Goulding, B. L. Ng, et al. 2010. Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. Science 329: 85-89.
27. Albu, D. I., J. VanValkenburgh, N. Morin, D. Califano, N. A. Jenkins, N. G. Copeland, P. Liu, and D. Avram. 2011. Transcription factor Bcl11b controls selection of invariant natural killer T-cells by regulating glycolipid presentation in double-positive thymocytes. Proc. Natl. Acad. Sci. USA 108: 6211-6216.
28. Williams, N. S., T. A. Moore, J. D. Schatzle, I. J. Puzanov, P. V. Sivakumar, A. Zlotnik, M. Bennett, and V. Kumar. 1997. Generation of lytic natural killer 1.1+, Ly-49- cells from multipotential murine bone marrow progenitors in a stroma-free culture: definition of cytokine requirements and developmental intermediates. J. Exp. Med. 186: 1609-1614.
29. Aliahmad, P., B. de la Torre, and J. Kaye. 2010. Shared dependence on the DNAbinding factor TOX for the development of lymphoid tissue-inducer cell and NK cell lineages. Nat. Immunol. 11: 945-952.
30. Albu, D. I., D. Califano, and D. Avram. 2010. Flow cytometry analysis of transcription factors in T lymphocytes. Methods Mol. Biol. 647: 377-390.
31. Vanvalkenburgh, J., D. I. Albu, C. Bapanpally, S. Casanova, D. Califano, D. M. Jones, L. Ignatowicz, S. Kawamoto, S. Fagarasan, N. A. Jenkins, et al. 2011. Critical role of Bcl11b in suppressor function of T regulatory cells and prevention of inflammatory bowel disease. J. Exp. Med. 208: 2069-2081.
32. Reynaud, D., E. Pietras, K. Barry-Holson, A. Mir, M. Binnewies, M. Jeanne, O. Sala-Torra, J. P. Radich, and E. Passegué. 2011. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 20: 661-673.
33. Carotta, S., S. H. Pang, S. L. Nutt, and G. T. Belz. 2011. Identification of the earliest NK-cell precursor in the mouse BM. Blood 117: 5449-5452.
34. Ramirez, K., K. J. Chandler, C. Spaulding, S. Zandi, M. Sigvardsson, B. J. Graves, and B. L. Kee. 2012. Gene deregulation and chronic activation in natural killer cells deficient in the transcription factor ETS1. Immunity 36: 921-932.
35. Quezada, S. A., T. R. Simpson, K. S. Peggs, T. Merghoub, J. Vider, X. Fan, R. Blasberg, H. Yagita, P. Muranski, P. A. Antony, et al. 2010. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207: 637-650.
36. Waldhauer, I., and A. Steinle. 2008. NK cells and cancer immunosurveillance. Oncogene 27: 5932-5943.
37. Kawano, Y., K. Taniguchi, A. Toshitani, and K. Nomoto. 1986. Synergistic defense system by cooperative natural effectors against metastasis of B16 melanoma cells in H-2-associated control: different behavior of H-2+ and H-2- cells in metastatic processes. J. Immunol. 136: 4729-4734.
38. Rodriguez, P. C., D. G. Quiceno, J. Zabaleta, B. Ortiz, A. H. Zea, M. B. Piazuelo, A. Delgado, P. Correa, J. Brayer, E. M. Sotomayor, et al. 2004. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64: 5839-5849.
39. Chiossone, L., J. Chaix, N. Fuseri, C. Roth, E. Vivier, and T. Walzer. 2009. Maturation of mouse NK cells is a 4-stage developmental program. Blood 113: 5488-5496.
40. Kim, S., K. Iizuka, H. S. Kang, A. Dokun, A. R. French, S. Greco, and W. M. Yokoyama. 2002. In vivo developmental stages in murine natural killer cell maturation. Nat. Immunol. 3: 523-528.
41. Ueda, Y., K. Yang, S. J. Foster, M. Kondo, and G. Kelsoe. 2004. Inflammation controls B lymphopoiesis by regulating chemokine CXCL12 expression. J. Exp. Med. 199: 47-58.
42. Zhang, S., M. Rozell, R. K. Verma, D. I. Albu, D. Califano, J. VanValkenburgh, A. Merchant, J. Rangel-Moreno, T. D. Randall, N. A. Jenkins, et al. 2010. Antigenspecific clonal expansion and cytolytic effector function of CD8+ T lymphocytes depend on the transcription factor Bcl11b. J. Exp. Med. 207: 1687-1699.
43. Takeda, K., M. Nakayama, M. Sakaki, Y. Hayakawa, M. Imawari, K. Ogasawara, K. Okumura, and M. J. Smyth. 2011. IFN-γ production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. J. Leukoc. Biol. 90: 777-785.
44. Mizrahi, K., J. Stein, I. Yaniv, O. Kaplan, and N. Askenasy. 2013. TNF-α has tropic rather than apoptotic activity in human hematopoietic progenitors: involvement of TNF receptor-1 and caspase-8. Stem Cells 31: 156-166.
45. Santiago-Schwarz, F., M. McCarthy, J. Tucci, and S. E. Carsons. 1998. Neutralization of tumor necrosis factor activity shortly after the onset of dendritic cell hematopoiesis reveals a novel mechanism for the selective expansion of the CD14-dependent dendritic cell pathway. Blood 92: 745-755.
46. Bryder, D., V. Ramsfjell, I. Dybedal, K. Theilgaard-Mönch, C. M. Högerkorp, J. Adolfsson, O. J. Borge, and S. E. Jacobsen. 2001. Self-renewal of multipotent long-term repopulating hematopoietic stem cells is negatively regulated by Fas and tumor necrosis factor receptor activation. J. Exp. Med. 194: 941-952.
47. Dybedal, I., D. Bryder, A. Fossum, L. S. Rusten, and S. E. Jacobsen. 2001. Tumor necrosis factor (TNF)-mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells. Blood 98: 1782-1791.
48. Rebel, V. I., S. Hartnett, G. R. Hill, S. B. Lazo-Kallanian, J. L. Ferrara, and C. A. Sieff. 1999. Essential role for the p55 tumor necrosis factor receptor in regulating hematopoiesis at a stem cell level. J. Exp. Med. 190: 1493-1504.
49. Pronk, C. J., O. P. Veiby, D. Bryder, and S. E. Jacobsen. 2011. Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors. J. Exp. Med. 208: 1563-1570.
50. Pearl-Yafe, M., K. Mizrahi, J. Stein, E. S. Yolcu, O. Kaplan, H. Shirwan, I. Yaniv, and N. Askenasy. 2010. Tumor necrosis factor receptors support murine hematopoietic progenitor function in the early stages of engraftment. Stem Cells 28: 1270-1280.
51. Duprez, L., N. Takahashi, F. Van Hauwermeiren, B. Vandendriessche, V. Goossens, T. Vanden Berghe, W. Declercq, C. Libert, A. Cauwels, and P. Vandenabeele. 2011. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity 35: 908-918.
52. Huys, L., F. Van Hauwermeiren, L. Dejager, E. Dejonckheere, S. Lienenklaus, S. Weiss, G. Leclercq, and C. Libert. 2009. Type I interferon drives tumor necrosis factor-induced lethal shock. J. Exp. Med. 206: 1873-1882.